Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness

Douglas S Robinson, Andrew M Bentley, Adele Hartnell, A Barry Kay, Stephen R Durham

Abstract

**Background** Bronchial mucosal inflammation and epithelial damage are characteristic features of asthma. Activation of T helper lymphocytes may contribute to this process by mechanisms including the release of cytokines promoting eosinophil infiltration and activation.

**Methods** Bronchial washings and bronchoalveolar lavage fluid were obtained from 29 atopic asthmatic patients (19 with current symptoms and 10 symptom free) and 13 normal volunteers. Flow cytometry was used to assess T cell phenotype and activation status in bronchoalveolar lavage fluid and peripheral blood, and differential cell counts were made on bronchial washings and bronchoalveolar lavage fluid. Findings were related to severity of disease as reflected by symptom scores, baseline lung function, and airway responsiveness.

**Results** CD4 T lymphocytes in bronchoalveolar lavage fluid and blood from asthmatic patients were activated by comparison with controls (CD4 CD25, median 16-8% v 8-7% for bronchoalveolar lavage fluid, and 15-3% v 8-7% in blood). Bronchoalveolar lavage fluid CD4 T cells from both asthmatic patients and controls were of memory phenotype (95-8% and 96-8% CD45RO and 1-7% and 0-4% CD45RA respectively), whereas both CD45RO and CD45RA T cells were present in blood. Patients with asthma and current symptoms showed increased bronchoalveolar T cell activation compared with patients without symptoms (CD4 CD25 18-7% v 12-3%). Within the asthmatic group there was a significant association between CD4 CD25 lymphocytes and asthma symptom scores ($r_s = 0.75$), airway methacholine responsiveness (log $PC_{20}$, $r_s = -0.43$) and baseline FEV$_1$. A correlation was also found between CD4 CD25 lymphocytes and eosinophils in bronchoalveolar lavage fluid ($r_s = 0.48$). Eosinophils in bronchoalveolar lavage fluid were increased in asthmatic patients compared with controls and the percentage of eosinophils in bronchoalveolar lavage fluid correlated with asthma symptom score. A relation was found between percentage of epithelial cells in bronchoalveolar lavage fluid and FEV$_1$ and methacholine PC$_{20}$.

**Conclusion** These results support the hypothesis that selective activation of memory CD4 T cells contributes to eosinophil accumulation, bronchial hyperresponsiveness, and symptoms in asthma.

(Thorax 1993;48:26–32)

Recent evidence has suggested that T lymphocyte activation and the recruitment and activation of eosinophils may be important in the development of airflow limitation in bronchial asthma. For example, peripheral blood CD4 T helper lymphocytes from patients with acute severe asthma expressed activation markers (interleukin-2 receptor (CD25), class II molecule (HLA DR), and the very late activation marker (VLA-1)) to a greater degree than those from controls. The degree of T lymphocyte activation was closely correlated with lung function and decreased with a time course that paralleled improvements in peak expiratory flow rates. Electron microscopical studies of bronchial biopsy specimens from asthmatic patients demonstrated mucosal lymphocyte irregularities suggestive of activation.

Immunohistological studies of such specimens showed increased numbers of cells in the mucosa expressing IL-2 receptor as shown by positive staining with a monoclonal antibody directed against CD25. Flow cytometry allows simultaneous identification of phenotypic and activation markers on cells in suspension. This has recently been applied to bronchoalveolar lavage fluid and blood cells from asthmatic patients. The results showed an increase in numbers of activated CD4 and CD8 T cells in both bronchoalveolar lavage fluid and blood from asthmatic patients compared with normal healthy non-atopic control subjects. Our own studies and those of other groups have shown that eosinophil numbers and eosinophil cationic protein concentrations in bronchoalveolar lavage fluid and bronchial biopsy specimens correlated with severity of asthma as...
Aktiviertes Memory T-Hilfzelle in Bronchoalveolarcherenspülungen von Patienten mit Asthma

Aktiviertes Memory T-Hilfzelle in Bronchoalveolarcherenspülungen von Patienten mit Asthma


Der Ziel dieser Studie war es, um die Lavagewebe von fiberoptischer Bronchoskopie von atemwegsasthmatischen Patienten mit normalen, gesunden Kontrollsubjekten. T-Zell-Phenotyp, memory state, und Aktivierung wurden durch Fluoreszenzzytometrie mit dual Immunofluoreszenz gestartet. Wir haben auch für die Beziehungen zwischen diesen Befunden und die Schwere der Erkrankung, als gemessen durch aktuelle Asthma-symptome und der Grad von bronchialer Hyperreagibilität durch inhalet Methacholin.**

**

**Methods**

**Patients**

Asthmatische Patienten (Tabelle 1) wurden ausgewählt, die Bewertung der allergischen Asthma und Lung Hospital, und freiwillige Mitarbeiter von der National Heart and Lung Institute. Alle Patienten wurden von einer informierten Einwilligung und die Genehmigung des Ethikkomitees. Sie waren alle Nichtraucher und weder hatten erhalten oder inhalte corticosteroiden innerhalb von drei Monaten vor der Studie. Die Diagnose von Asthma basiert auf (1) ein klinische Anamnese von wheezing, cough, or shortness of breath; (2) dokumentierten 15% Variabilität in der exspiratorischen Werte in einem (FEV1) oder Peak Expiratory Flow Rate (PEF); und (3) einen Methacholin PC20 (provocation concentration causing a 20% fall in FEV1 from baseline) weniger als 8 mg/ml (fünf der saisonalen Asthma-Patienten ohne Symptome hatte einen PC20 von 8 mg/ml oder weniger). Alle asthmatischen Patienten waren atopic as defined by (1) positive skin prick tests to one or more extracts of the common aeroallergens: house dust (Dermatophagoides pteronyssinus), Timothy grass pollen, cat, dog, feathers, tree pollen, Aspergillus fumigatus, and (2) raised serum allergen specific IgE concentrations, as determined by radioallergosorbent test (grade 2 or more on a scale of 1–4, Phadebas RAST, Pharmacia, Sweden) to house dust mite, cat, or grass pollen allergens. Nineteen asthmatic patients were atopic as defined by wheeze or chest tightness requiring the use of inhaled β2 agonists more than twice a week. Ten asthmatic patients had strictly allergen related symptoms and had no symptoms when studied out of season or after allergen avoidance. To define the severity of Asthma symptoms an Aas symptom score[19] was allocated on the basis of a questionnaire administered by a clinician who was not involved in the laboratory measurements (AMB). The FEV1 was measured with a dry bellows spirometer (Vitalograph, Buckingham, UK). Methacholin PC20 was measured between 0800 and 0900 at least 48 hours before bronchoscopy. Normal volunteers were without symptoms and had negative skin prick responses, low total IgE, and no detectable serum allergen specific IgE to common aeroallergens.

**Fiberoptic Bronchoscopy**

Alle fiberoptischen Bronchoskopien wurden durchgeführt vom gleichen Operator (SRD) zwischen 0800 und 0900. Asthmatische Patienten and normal subjects wurden prämediziert mit 2.5 mg von Nebulisation Salbutamol, intravenöser Atropin (0.5 mg), und Midazolam als erforderlich für Sedation (5–10 mg). Topikal Anaesthesie war mit 2% Lidocaine. Supplemental oxygen wurde at 4 l/minute throughout. Arterial Oxygen saturation wurde monitorned by pulse oximeter (Ohmeda, Harlow, UK). The bronchoscope (Olympus Corporation, Tokyo, Japan) wurde wedged at segmental or subsegmental level in

---

**Tabelle 1: Klinische Daten der untersuchten Patienten**

<table>
<thead>
<tr>
<th>Age (mean, range)</th>
<th>Asymptomatic</th>
<th>Without symptoms</th>
<th>Normal subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 (22–27)</td>
<td>26 (19–35)</td>
<td>25 (19–33)</td>
<td></td>
</tr>
<tr>
<td>14 W, 5 M</td>
<td>5 W, 5 M</td>
<td>7 W, 6 M</td>
<td></td>
</tr>
<tr>
<td>82 (62–108)</td>
<td>103 (84–129)</td>
<td>111 (87–115)</td>
<td></td>
</tr>
<tr>
<td>PC20 (mg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.6 (0.24–3.2)</td>
<td>10.4 (2.2–19.9)</td>
<td>&gt; 32</td>
<td></td>
</tr>
</tbody>
</table>

W, Dämm; M, Mann.
FLOW CYTOMETRY AND CYTOCENTRIFUGE PREPARATIONS

The total volume of bronchoalveolar lavage fluid recovered was noted. Any mucus was removed by filtration through sterile cotton gauze. Bronchoalveolar lavage fluid cells were centrifuged (300 g at 4°C) for seven minutes, washed in Roswell Park Memorial Institute medium (RPMI) 1640 (Flow Laboratories, Irvine, Scotland), and resuspended in RPMI 1640 with 25 mM HEPES, 0.5% BSA, and 0.1% sodium azide. A total cell count was performed on a Neubauer haemocytometer. Cytocentrifuge preparations were made with a Shandon 2 cytopsin (Shandon Southern Instruments, Runcorn, UK) at 800 rpm for five minutes for differential counts (stained with May–Grunwald Giemsa). Bronchial washings were not filtered but cells were pelleted as for bronchoalveolar lavage fluid and resuspended in RPMI 1640 before cytocentrifuge preparations were made. Peripheral blood mononuclear cells were separated on Ficoll-Paque (Pharmacia, Milton Keynes, UK) and resuspended in RPMI 1640. Aliquots of 5 x 10⁵ cells were incubated for 15 minutes at 4°C with monoclonal antibodies directly conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE); CD3-PE, CD4-PE, CD8-PE, CD3-FITC, CD4-FITC, CD45RA-FITC, and IgG1-FITC and IgG2-PE isotype controls were from Becton Dickinson, Cowley, UK; CD25-FITC, HLA DR-FITC, and CD45RO-FITC were from Dako High Wycombe, UK; and VLA-1-FITC was from Laboratory Impex, Twickenham, UK. After two washes in medium, cells were resuspended for analysis in Isoton II balanced electrolyte solution (Coulter Electronics, Luton, UK). A Becton-Dickinson FACS Analyser with FACSLite 488 nm Argon ion laser was used to collect 10 000 events in a gate defined by volume and 90° light scatter of peripheral blood lymphocytes. Cells positively stained for T cell phenotypic markers (CD4, CD8) were analysed for staining with activation or memory markers. Results were expressed as % positive relative to an isotype control antibody. One aliquot of cells was stained with CD3-PE and CD4-FITC to exclude monocytes or macrophages. One aliquot was also stained with CD4-PE and CD3-FITC to confirm that all CD4 cells analysed were lymphocytes.

Differential cell counts of bronchoalveolar lavage fluid and bronchial washings were performed blind by counting 600 cells on cytocentrifuge preparations stained by May–Grunwald Giemsa stain.

STATISTICAL ANALYSIS

Results for flow cytometry and cell counts for asthmatic patients and controls were compared with the Mann-Whitney U test and a standard computer software package (Ministat Inc, State College, Pennsylvania). Results of Mann-Whitney U tests are given as median values for each group, the estimated median difference, and the 95% confidence interval (95% CI) for this difference. Correlation coefficients were obtained by Spearman’s rank method.

Where multiple comparisons were made, Bonferroni’s correction was applied. p values < 0.05 were considered significant.

Results

Fibreoptic bronchoscopy was well tolerated by all subjects. Occasional mild bronchospasm in several subjects induced by the procedure was rapidly reversed by the administration of nebulised salbutamol.

There was a small but significant reduction in the total bronchoalveolar lavage fluid recovered from asthmatic patients compared with normal subjects (median 115 ml vs 130 ml, estimated median difference —20.0; 95% CI for difference —35.0 to 0.01, p < 0.05). There was no difference in total cell recovery between the two groups.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Asthmatic patients (n = 29)</th>
<th>Controls (n = 13)</th>
<th>Estimated median difference (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (range)</td>
<td>Median (range)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages</td>
<td>84.5 (50.3–90.2)</td>
<td>85.3 (77.8–94.0)</td>
<td>—2.4 (—7.3 to 2.3)</td>
<td>0.32</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>11.3 (7.2–23.5)</td>
<td>14.3 (4.5–22.2)</td>
<td>—2.6 (—6.0 to 1.40)</td>
<td>0.13</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>1.8 (0.1–26.3)</td>
<td>0.4 (0.0–1.5)</td>
<td>1.4 (0.5 to 4.0)</td>
<td>0.0007</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0.5 (0.0–52)</td>
<td>0.2 (0.0–2.0)</td>
<td>0 (—0.3 to 0.3)</td>
<td>0.96</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>0.1 (0.0–10.0)</td>
<td>0.2 (0.0–0.8)</td>
<td>0 (—0.2 to 0.1)</td>
<td>0.83</td>
</tr>
</tbody>
</table>

|                | Bronchoalveolar lavage       |                        |                                      |     |
|                |                              |                        |                                      |     |
| Macrophages    | 71.5 (26.0–96.0)             | 73.8 (48.0–86.5)       | 4.3 (—8.1 to 14.0)                   | 0.58|
| Lymphocytes    | 5.5 (7.2–23.5)               | 6.2 (4.5–22.2)         | —0.1 (—2.3 to 2.2)                   | 0.94|
| Eosinophils    | 3.8 (0.4–46.3)               | 0.2 (0.0–3.5)          | 3.2 (1.3 to 6.5)                     | 0.0001|
| Neutrophils    | 1.3 (0.0–7.9)                | 0.61 (1.0–19.0)        | —6.2 (—8.6 to 3.7)                   | 0.0001|
| Epithelial cells | 5.0 (0.0–57.7)             | 12.8 (0.7–43.4)       | —6.8 (—12.9 to 1.1)                  | 0.08|

*pCounts in bronchial washings from 25 asthmatic patients (four were too mucoid for analysis).
Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma

Table 3  Percentages of CD4 and CD8 T cells in bronchoalveolar lavage fluid from asthmatic patients and controls expressing activation and memory markers

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Asthmatic patients (n = 29)</th>
<th>Controls (n = 13)</th>
<th>Estimated median difference (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4/CD25</td>
<td>16.8 (4.9–29.8)</td>
<td>8.7 (5.1–15.1)</td>
<td>6.7 (3.8 to 10.4)</td>
<td>0.0001</td>
</tr>
<tr>
<td>CD4/HLA DR</td>
<td>48.8 (22.3–78.0)</td>
<td>36.0 (11.3–60.0)</td>
<td>11.4 (–0.3 to 22.1)</td>
<td>0.061</td>
</tr>
<tr>
<td>CD4/HLA DR</td>
<td>23.1 (3.3–57.3)</td>
<td>16.0 (2.4–31.9)</td>
<td>6.4 (–4.0 to 16.2)</td>
<td>0.13</td>
</tr>
<tr>
<td>CD4/CD45RO</td>
<td>95.8 (51.5–99.5)</td>
<td>96.8 (73.3–99.2)</td>
<td>–0.5 (–2.8 to 2.1)</td>
<td>0.55</td>
</tr>
<tr>
<td>CD4/CD45RA</td>
<td>1.7 (0–13.0)</td>
<td>0.4 (0–1.9)</td>
<td>1.3 (0.4 to 3.2)</td>
<td>0.03</td>
</tr>
<tr>
<td>CD8/CD25</td>
<td>3.9 (0–153)</td>
<td>3.6 (0–10.9)</td>
<td>0.3 (–2.2 to 2.6)</td>
<td>0.78</td>
</tr>
<tr>
<td>CD8/HLA DR</td>
<td>48.2 (19.1–78.8)</td>
<td>42.9 (22.3–60.6)</td>
<td>5.4 (–2.6 to 15.2)</td>
<td>0.19</td>
</tr>
<tr>
<td>CD8 VLA I</td>
<td>53.6 (32.3–83.8)</td>
<td>51.0 (37.7–73.8)</td>
<td>5.8 (–6.6 to 16.1)</td>
<td>0.26</td>
</tr>
</tbody>
</table>

groups (1.0 × 10^4 cells/ml in asthmatic patients and 0.9 × 10^5 cells/ml in controls).

**DIFFERENTIAL CELL COUNTS**

Bronchial washings from four of the asthmatic patients were too mucoid to allow processing and were excluded from analysis. There was a significant increase in cell numbers and percentage of eosinophils in both bronchial washings and bronchoalveolar lavage fluid from asthmatic patients compared with controls (table 2). A reduction in percentage of neutrophils was found in bronchial washings but not bronchoalveolar lavage fluid from asthmatic patients (table 2). Bronchial washings from both asthmatic patients and controls showed a reduced percentage of lymphocytes and increased neutrophils and epithelial cells when compared with cell counts in bronchoalveolar lavage fluid (table 2).

**FLOW CYTOMETRY**

Expression of CD25 by CD4 T cells in bronchoalveolar lavage fluid was significantly greater for asthmatic patients than for controls (table 3). The difference in expression of HLA DR by CD4 lavage T cells in the two groups did not reach significance and there was no significant difference in expression of VLA-1. There were no differences in expression of activation markers by CD8 T cells. Bronchoalveolar lavage fluid CD4 T cells were CD45RO + CD45RA --, whereas both phenotypes were present in blood (table 3). There was a small but significant increase in CD45RA expression by CD4 cells in bronchoalveolar lavage fluid (1.7% vs 0.4%), but no difference in CD45RO between asthmatic patients and controls.

**ASTHMATIC PATIENTS WITH AND WITHOUT SYMPTOMS**

There was a significant increase in CD25 expression by CD4 lavage T cells in symptomatic asthmatic patients compared with those without current symptoms, and with normal healthy control subjects (fig 1). Eosinophil numbers or percentages in bronchial washings or bronchoalveolar lavage fluid were not different between asthmatic patients with and without symptoms. There was a significantly higher percentage of epithelial cells, however, from symptomatic asthmatic patients compared with patients without symptoms in both bronchial washings (7.7% v 1.5, estimated median difference 6.3, 95% CI 1.5 to 37.0, p < 0.05) and bronchoalveolar lavage fluid (0.2% v 0.0, estimated median difference 0.2, 95% CI 0 to 0.5, p < 0.05).

**PERIPHERAL BLOOD LYMPHOCYTES**

Flow cytometric analysis of peripheral blood lymphocytes revealed increased expression of CD25 and HLA DR by CD4 cells from asthmatic patients compared with control subjects (15.3% positive v 8.7%, estimated median difference 6.3, 95% CI 2.6 to 10.2, p < 0.001 for CD25, 7.3% v 4.3%, estimated median difference 3.5, 95% CI 1.3 to 6.0, p < 0.01 for HLA DR). There was no significant difference in the expression of VLA-1 (1.2 v 1.3%), CD45RO (42.3% v 37.2%), or CD45RA (52.3% v 54.1%). There was increased expression of HLA DR by CD8 PBL from asthmatic patients compared with controls (19.6% v 8.9, estimated median difference 10.3, 95% CI 2.5 to 20, p < 0.01), but the difference in expression of CD25 was not significant (3.1% v 1.7%) and there was no difference in expression of VLA-1 (0.8% v 1.0%).

**ASSOCIATION WITH ASTHMA SEVERITY**

Associations were assessed among the level of CD25 expression by CD4 cells in bronchoalveolar lavage fluid, severity of asthma, and the degree of bronchoalveolar lavage fluid eosinophilia within the asthmatic patients (fig 2).
cells. This suggests that T cell activation, eosinophil recruitment, and epithelial shedding may possibly be linked and represent a final common pathway in the development of airway narrowing, hyperresponsiveness, and symptoms in atopic allergic asthma.

Bronchoalveolar lavage has been used widely in the investigation of asthma and is safe and well tolerated provided agreed guidelines are followed. It has been suggested that small volume lavage gives a more proximal sample of airway cells than does conventional bronchoalveolar lavage, and may be more appropriate to the study of airway disease. Labelling studies have shown, however, that bronchoalveolar lavage does sample small airways, and this may be important given their contribution to abnormalities of lung function in asthma. We did not study T cell activation in bronchial washings because of the small numbers of cells recovered, their low viability relative to bronchoalveolar lavage fluid, and the potential problems from mucus in flow cytometry, but have confirmed that cellular changes in asthma are broadly similar in bronchial washings and bronchoalveolar lavage fluid. Previous studies have found increases in eosinophils and epithelial cells in both bronchial washings and bronchoalveolar lavage fluid from asthmatic patients compared with control subjects and have indicated a correlation between numbers of these cell types and the amount of bronchial responsiveness. The detection of increased concentrations of major basic protein and eosinophil cationic protein in bronchoalveolar lavage fluid from asthmatic patients, together with the potential of these eosinophil granule proteins to damage respiratory epithelium in vitro, supports the hypothesis that eosinophil mediated epithelial injury may contribute to airway lability in asthma. Because epithelial cells (and neutrophils) were also prominent, however, in bronchial washings from some normal control subjects caution must be exercised in attributing epithelial cell loss to asthma. Infiltration of eosinophils and subsequent activation in the bronchial mucosa may occur, at least in part, as a consequence of T lymphocyte activation with the production of cytokines that recruit and modify eosinophil function.

The finding of increased expression of CD25 by cells in bronchoalveolar lavage fluid from asthmatic patients is in agreement with a recent report which showed relations among CD25 expression, lung function (FEV₁), airway methacholine responsiveness, and bronchoalveolar lavage fluid eosinophilia. These investigators found increased expression of HLA DR and VLA-1 by CD4 bronchoalveolar lavage fluid lymphocytes and increased expression of activation markers by CD8 T cells in bronchoalveolar lavage fluid. As in some, but not all, previous reports they described an increase in lymphocytes in bronchoalveolar lavage fluid from asthmatic patients. We did not find increased expression of the late activation markers (HLA DR, VLA 1) by bronchoalveolar lavage CD4 T cells, or activation of

Discussion
In this study, which was based on fibreoptic bronchoscopy of a large group of atopic asthmatic patients with a broad range of clinical disease, we have shown that T lymphocytes obtained by bronchoalveolar lavage are activated as reflected by an increase in expression of CD25. This increase was confined to CD4 T cells that were of memory phenotype. The degree of T cell activation in bronchoalveolar lavage fluid was closely related to severity of asthma as judged by an asthma symptom score as well as baseline lung function and the degree of airway responsiveness. Associations were also found between bronchoalveolar lavage fluid eosinophilia and symptoms of asthma, and between numbers of activated T cells, eosinophils, and epithelial

Figure 2 Relation between the degree of bronchoalveolar lavage (BAL) T cell activation and (A) eosinophilia (r = 0.48, p < 0.001), (B) asthma severity as assessed by FEV₁ (r = −0.39, p < 0.05), (C) airway responsiveness (r = −0.43, p < 0.05), and (D) asthma symptoms (Aas score) (r = 0.75 p < 0.001).
CD8 cells. Although these differences may reflect our slightly younger study group there were no obvious differences in our subjects for severity of asthma or atopic state. Peripheral blood lymphocytes from patients with acute severe asthma showed increased expression of activation markers (CD25, HLA DR and VLA-1) by CD4, but not CD8, cells compared with control subjects and patients with chronic obstructive airways disease. Activation of T cells was also suggested by the increased numbers of cells staining for CD25 in bronchial biopsy specimens from asthmatic patients, and double immunostaining has recently confirmed that most of the increased CD25 expression in such biopsy specimens is indeed on CD3 T lymphocytes rather than alternative cells such as macrophages.

The explanation for increased expression of late activation markers by lymphocytes in bronchoalveolar lavage fluid compared with those from peripheral blood may lie in the finding that lavage CD4 T cells were of memory phenotype (CD45RO+CD45RA-). This is in agreement with previous studies of bronchoalveolar lavage fluid from healthy volunteers and patients with interstitial lung disease. The small increase in percentage of CD4 cells in bronchoalveolar lavage fluid expressing CD45RA in asthmatic patients compared with controls is of doubtful biological significance. Previous activation leading to memory status may explain continued expression of late activation markers; indeed the \( \beta_1 \) chain of VLA-1 (CD29) has been used as a marker of memory T cells. Airway T cells might be expected to encounter antigens frequently, and the transient expression of CD25, rather than the more prolonged expression of late activation markers, might more accurately reflect ongoing allergenic T cell stimulation in asthma.

It is possible that the increased level of T lymphocyte activation and eosinophilia that we found in our atopic asthmatic patients may reflect the atopic state rather than asthma itself. Further studies including a group of non-atopic subjects would be required to exclude this possibility. The correlation with severity of asthma shown here, however, together with findings from studies of peripheral blood and bronchial mucosal biopsy samples from both extrinsic and intrinsic asthmatic patients, strongly supports the role of CD4 T cell activation in asthma, rather than simply the atopic state.

The Aas symptom score that we employed uses five categories of asthma based on severity and duration of attacks, resting lung function, and treatment requirements. No grading system of asthma is widely accepted as satisfactory, but this system does allow stratification of patients and our findings concur with a previous report of significant correlations between the Aas symptom score and bronchoalveolar lavage fluid eosinophilia and concentrations of eosinophil cationic protein in bronchoalveolar lavage supernatant fluid.

In conclusion we have shown increased expression of an early activation marker by memory CD4 T cells in bronchoalveolar lavage fluid from patients with atopic asthma.

Adventitia

It is a matter of conjecture whether my spell at the Army chest centre in 1957-8 helped to shape my future career. It was certainly time well spent. I was posted from an army unit to the Connaught Hospital, near Hindhead, Surrey, as the first epidemic of the "Asian" flu was widening. The effects of the epidemic had been quite dramatic and we had been very busy, with barrack rooms doubling as sick bays where the few not affected and those convalescing from the acute phase of the illness helped to care for those laid low by the virus. It was as much as a regimental medical officer could do to get round the unit to examine any soldier whose illness or progress was out of the ordinary, and thus it was that one picked up the patients with staphylococcal pneumonia. My experience with this disease and its complications was soon to be consolidated at the Army chest centre, where we saw many cases, and the lessons learned stood one in good stead for years to come.

The striking opportunism of the staphylococcus as a cause of pneumonia during influenza epidemics is less evident today, and indeed in recent years staphylococcal pneumonia has presented itself as a sporadic and infrequent event. Now we seem to be much more concerned with Pneumocystis carinii pneumonia and other infections that are also opportunistic, but for different reasons. It surprised me 35 years ago, and still does, that a necrotising pneumonia that so often led to the formation of multiple cavities within the lung was not more often a cause of life threatening haemorrhage. Although I have seen this happen it has been a rare event. I recall one patient, an extremely ill young woman, whose haemopysis ceased when the blood throughout her left bronchial tree clotted to form a perfect bronchial cast, resulting in the collapse of that lung. The bronchial thrombus could be removed only by piecemeal extraction at bronchoscopy. I remember also that she went on to suffer widespread staphylococcal osteitis but eventually made a complete recovery.

As at any chest unit in the 1950s, tuberculosis was a major item. Primary pulmonary tuberculosis and pleural effusions were commonplace and there was a wealth of experience with post-primary disease, which was often extensive at the time of diagnosis. Happily, treatment regimens were well established and effective. Resectional surgery was still in vogue for selected patients in whom gross residual disease persisted after adequate chemotherapy, in case the disease was quiescent but not cured and might later relapse. Besides the surgery that was offered to regular British soldiers there was in progress a programme of such treatment for Gurkhas, who were transferred from Malaya for operation after completing their medical care at the British Military Hospital in Kinrara. The presence of these cheerful men was a notable feature of life in the hospital at that time. It was rumoured that while being prepared for their proposed operation some of the Gurkhas had been given to understand that this was needed in the fight against their enemy within, and that the resulting chest wound would represent an honourable battle scar and a successful outcome. Although this is no doubt apocryphal it does illustrate the paternalism that pervaded our profession at that time.

We were fortunate to see a wide variety of chest diseases, some of them uncommon, such as pulmonary arteriovenous aneurysms, sequestrated segments, and the Hamman-Rich syndrome (as it was then called, still "in its infancy" and apparently rare). Competence was gained in the investigative techniques of the day and in interpretation of chest radiographs, tomograms, and bronchograms. We became quite adept at bronchography, and it was surprising how often underlying bronchectasis was identified in our population of patients, who until their recent acute illness had been "fighting fit" and gave no previous history of lung disease.

A sense of humour prevailed. On the occasion of the arrival of a new commanding officer an addendum mysteriously appeared overnight in large block capitals beneath the name of the hospital on the signboard facing the main road:

UNDER NEW MANAGEMENT,
OLD BOY!

I know of no instance where any of the recently appointed NHS trust hospital managers has been similarly greeted. Such was the spirit of the times.—T B STRETTON
Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness.

D S Robinson, A M Bentley, A Hartnell, A B Kay and S R Durham

Thorax 1993 48: 26-32
doi: 10.1136/thx.48.1.26

Updated information and services can be found at:
http://thorax.bmj.com/content/48/1/26

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/